This ASO, developed by Ionis Pharmaceuticals, Inc., is designed to target angiotensinogen (AGT) and, consequently, inhibit RAAS pathways, acting as a therapeutic approach for the treatment of hypertension and HF conditions. Here, AGT is linked to hypertensive disorder.